Loading...
•
Dec 31, 2024
Zomedica Q4 2024 Earnings Report
Zomedica reported record Q4 revenue, strong gross margins, and a reduced net loss compared to the prior year.
Key Takeaways
Zomedica's Q4 2024 revenue grew to $7.9 million, an 8% increase year-over-year, driven by 109% growth in its Diagnostics segment. The company reported a net loss of $7.2 million, a significant improvement from the $22.4 million net loss in Q4 2023. Gross margin was strong at 70.3%, while non-GAAP adjusted EBITDA loss improved to $5.4 million. Cash and cash equivalents at the end of the quarter stood at $71.4 million, supporting future growth initiatives.
Q4 2024 revenue reached a record $7.9 million, up 8% year-over-year.
Diagnostics segment revenue surged 109%, driven by TRUFORMA® adoption.
Net loss narrowed to $7.2 million, improving from $22.4 million in Q4 2023.
Strong cash position of $71.4 million provides growth runway.
Revenue by Segment
Forward Guidance
Zomedica expects continued growth in 2025, driven by increased focus on equine markets, product launches, and strategic acquisitions.
Positive Outlook
- Expansion into equine healthcare with new product launches.
- Increased adoption of TRUFORMA® and VETGuardian® driving revenue growth.
- Optimized manufacturing capabilities to improve efficiency and margins.
- Strong cash position enables further strategic acquisitions.
- New distribution agreements expanding international reach.
Challenges Ahead
- Potential pricing pressure in the diagnostic segment.
- Competition intensifying in the veterinary diagnostics market.
- Macroeconomic uncertainty affecting capital spending by veterinary clinics.
- Higher R&D and marketing costs to support growth initiatives.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...